SCHEMBL4285619

SCHEMBL4285619

COC(=O)C(C)(C)C(O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.62
▸ KDM4E B2RXH2 1/20 0.62
▸ CYP26A1 O43174 1/20 0.54
▸ POLB P06746 2/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ HPGD P15428 1/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ MAPT P10636 1/20 0.48
▸ ADRB2 P07550 1/20 0.45
▸ ADRB1 P08588 1/20 0.45
▸ ADRB3 P13945 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27746503 0.79 ALDH1A1 (0.49) ALDH1A1KDM4ECYP26A1POLBCYP2C19
SCHEMBL4284433 0.78 ESR1 (0.44) ALDH1A1KDM4ECYP26A1CYP2C19ADRB2
SCHEMBL16651165 0.78 ALDH1A1 (0.72) ALDH1A1KDM4EHPGDNPC1MEN1
SCHEMBL27746530 0.77 POLB (0.49) ALDH1A1KDM4ECYP26A1POLBCYP2C19
SCHEMBL4278598 0.77 ADRB2 (0.40) CYP26A1CYP2C19ADRB2ADRB1ADRB3
SCHEMBL2874789 0.77 SLC6A3 (0.52) ALDH1A1KDM4EPOLBNPC1MEN1
SCHEMBL14478233 0.77 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDNPC1MEN1
SCHEMBL10905859 0.76 KCNN4 (0.50) ALDH1A1CYP26A1CYP2C19KMT2AMAPK1
SCHEMBL4175638 0.76 ALDH1A1 (0.68) ALDH1A1KDM4EHPGDNPC1MEN1
SCHEMBL429356 0.76 ALDH1A1 (0.65) ALDH1A1POLBCYP2C19HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234363-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-09-16 — — US disclosed
US-20100234363-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-09-16 — — US disclosed
WO-2009153566-A1 CYP26 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-23 — — WO disclosed
WO-2009153566-A1 CYP26 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234363-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE HSD11B1, HSD11B2, HSD3B1 ALDH1A1 165/4885KDM4E 1936/4885CYP26A1 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback